Stock Analysis on Net
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Common-Size Income Statement
Quarterly Data

Allergan Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010 Sep 30, 2010 Jun 30, 2010 Mar 31, 2010
Product net sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales, excludes amortization of intangible assets -11.07 -11.54 -12.16 -12.63 -12.33 -12.58 -12.63 -13.95 -12.74 -13.57 -13.75 -14.34 -13.16 -14.35 -13.95 -14.63 -14.17 -14.91 -15.53 -15.39
Amortization of intangible assets -1.46 -1.62 -1.53 -1.72 -1.70 -1.88 -1.84 -2.14 -2.24 -2.39 -2.27 -2.31 -2.31 -2.43 -2.23 -2.59 -2.52 -2.61 -3.03 -3.36
Gross profit 87.47% 86.84% 86.31% 85.65% 85.97% 85.54% 85.54% 83.90% 85.02% 84.04% 83.99% 83.35% 84.52% 83.22% 83.83% 82.77% 83.31% 82.48% 81.44% 81.25%
Other revenues 1.14 1.47 2.02 1.67 1.49 1.98 1.31 1.89 1.64 1.64 1.64 1.92 1.41 1.32 1.20 1.47 1.49 1.36 1.26 4.42
Selling, general and administrative -39.44 -39.91 -39.34 -40.68 -43.11 -38.56 -38.67 -42.22 -37.58 -38.88 -39.84 -42.84 -39.91 -41.07 -40.47 -47.05 -40.89 -43.40 -40.51 -42.85
Research and development -14.05 -16.11 -15.80 -21.56 -16.23 -16.85 -16.90 -17.37 -16.12 -21.08 -15.81 -16.48 -16.37 -16.88 -18.38 -15.78 -15.53 -16.28 -15.23 -20.14
Legal settlement 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 -51.17 0.00 0.00
Impairment of intangible assets and related costs 0.00 0.00 0.00 0.00 -0.69 0.00 0.00 0.00 -1.50 0.00 0.00 0.00 0.00 -0.33 -0.24 -1.29 0.00 -30.96 0.00 0.00
Restructuring (charges) reversal -1.94 -10.36 0.08 -1.50 -0.04 -0.04 0.00 -0.30 -0.07 -0.27 -0.06 0.00 0.00 0.01 -0.01 -0.37 0.04 -0.01 -0.01 -0.05
Operating income (loss) 33.18% 21.94% 33.27% 23.59% 27.40% 32.07% 31.27% 25.91% 31.39% 25.45% 29.91% 25.95% 29.65% 26.27% 25.94% 19.76% 28.48% -57.97% 26.95% 22.64%
Interest income 0.08 0.11 0.13 0.11 0.10 0.10 0.13 0.11 0.13 0.14 0.12 0.09 0.09 0.14 0.11 0.18 0.25 0.13 0.10 0.12
Interest expense -0.83 -1.03 -1.08 -0.97 -1.10 -1.27 -1.27 -1.21 -1.00 -1.14 -1.17 -1.16 -1.21 -1.16 -1.09 -1.97 -2.15 -1.71 -1.13 -1.50
Other, net 1.13 2.40 -0.89 -0.40 0.16 -1.01 0.71 -0.61 -0.26 -0.66 0.33 -1.10 -0.79 1.97 -0.39 -0.79 -0.76 -1.50 1.16 -0.27
Non-operating income (expense) 0.38% 1.49% -1.83% -1.25% -0.83% -2.19% -0.43% -1.71% -1.12% -1.67% -0.72% -2.17% -1.90% 0.95% -1.37% -2.58% -2.67% -3.08% 0.13% -1.65%
Earnings (loss) from continuing operations before income taxes 33.56% 23.42% 31.43% 22.33% 26.57% 29.89% 30.84% 24.20% 30.26% 23.78% 29.19% 23.78% 27.75% 27.21% 24.56% 17.18% 25.81% -61.05% 27.08% 20.98%
(Provision) benefit for income taxes -4.83 -5.94 -8.54 -6.37 -7.74 -8.11 -8.40 -5.14 -8.36 -5.77 -9.00 -6.92 -7.52 -8.07 -6.81 -4.50 -5.42 4.95 -7.47 -5.70
Earnings (loss) from continuing operations 28.72% 17.48% 22.90% 15.97% 18.84% 21.78% 22.45% 19.06% 21.90% 18.01% 20.20% 16.86% 20.23% 19.14% 17.75% 12.68% 20.39% -56.10% 19.61% 15.28%
Earnings from discontinued operations, net of applicable income tax 0.00 0.00 0.00 0.00 0.06 0.36 0.46 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Gain (loss) on sale of discontinued operations, net of applicable income tax -0.19 0.02 0.00 -0.04 -0.08 -2.46 0.00 -18.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Discontinued operations -0.19% 0.02% 0.00% -0.04% -0.02% -2.10% 0.46% -18.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net earnings (loss) 28.54% 17.50% 22.90% 15.93% 18.82% 19.68% 22.90% 1.01% 21.90% 18.01% 20.20% 16.86% 20.23% 19.14% 17.75% 12.68% 20.39% -56.10% 19.61% 15.28%
Net earnings attributable to noncontrolling interest -0.10 -0.05 -0.07 -0.04 0.04 -0.07 -0.08 -0.13 -0.07 -0.09 -0.07 -0.04 0.01 -0.09 -0.14 -0.04 0.00 -0.15 -0.11 -0.10
Net earnings (loss) attributable to Allergan, Inc. 28.44% 17.45% 22.83% 15.89% 18.85% 19.62% 22.82% 0.87% 21.84% 17.93% 20.13% 16.83% 20.23% 19.05% 17.61% 12.64% 20.39% -56.25% 19.49% 15.18%

Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Allergan Inc. operating income (loss) as a percentage of product net sales decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 not reaching Q2 2014 level.
Earnings (loss) from continuing operations before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Allergan Inc. earnings (loss) from continuing operations before income taxes as a percentage of product net sales decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 exceeding Q2 2014 level.
Net earnings (loss) attributable to Allergan, Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Allergan Inc. net earnings (loss) attributable to Allergan, Inc. as a percentage of product net sales decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 exceeding Q2 2014 level.